This site is intended for health professionals only

Wednesday 19 June 2019
LatestNews
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
 
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Fri, 8 Jun 2007
An ECDC report has highlighted the poor state of infections in EU hospitals
Fri, 8 Jun 2007
A study has successfully piloted an "over the phone" heart rhythm monitoring scheme
Wed, 6 Jun 2007